Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Lexeo Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Lexeo Therapeutics, Inc.

LXEO

Lexeo Therapeutics, Inc.

About Lexeo Therapeutics, Inc.

Lexeo Therapeutics is a clinical-stage genetic medicine company focused on developing gene therapies for cardiovascular diseases caused by genetic mutations. Its core programs target conditions like Friedreich ataxia cardiomyopathy, arrhythmogenic cardiomyopathy, hypertrophic cardiomyopathy, and neurodegenerative disorders such as Alzheimer’s disease. Utilizing AAV vector technology, the company aims to address underlying genetic causes, offering potentially transformative, disease-modifying treatments for high unmet medical needs in large patient populations.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Lexeo Therapeutics, Inc.

1
1
Lexeo Therapeutics, Inc. Lexeo Therapeutics Reports $20.2 Million Net Loss in Q1 2026, Improved from $32.7 Million in Q1 2025

Via official filing (AI summary) | 25 days ago | 0 comments

2
1
Lexeo Therapeutics, Inc. Lexeo Therapeutics Reports 2025 Financial Results and Clinical Advancements

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Lexeo Therapeutics, Inc. Lexeo Therapeutics Reports Q3 2025 Financial Results with Improved Net Loss

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Lexeo Therapeutics, Inc. Lexeo Therapeutics Reports $26.1 Million Net Loss in Q2 2025, Highlights Clinical Advancements

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Lexeo Therapeutics, Inc. Lexeo Therapeutics Reports $32.7 Million Net Loss in Q1 2025, Increases Operating Expenses

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Lexeo Therapeutics, Inc. Lexeo Therapeutics Reports $98.3 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Lexeo Therapeutics, Inc. Lexo Therapeutics Reports Financial Results, Advances Clinical Programs Amid Ongoing Losses

Via official filing (AI summary) | over 1 year ago | 0 comments